Microdose semaglutide and microdose tirzepatide are informal terms for prescribing below the approved titration ladder, at a provider's discretion. The molecules differ in receptor targets, starting rungs and formats, which is why microdosed tirzepatide at Telos Rx is assessed individually.
Most comparisons of these two drugs argue about which produces more weight loss at full dose. Microdosing searchers are asking something different: if a reduced dose is on the table, does the choice of molecule change anything?
Neither Molecule Has an Official Microdose
Microdosing is not an FDA-approved concept. There is no approved microdose product, no approved microdose label, and no official definition of what amount counts as a microdose of either drug.
The term describes prescribing below the standard labelled titration, decided by a provider for an individual. With no agreed threshold, two clinics can use the word to mean different things. Background sits in GLP-1 microdosing explained and what counts as a microdose of tirzepatide.
One Receptor Target or Two
Semaglutide is a GLP-1 receptor agonist, acting on a single incretin pathway involved in appetite signalling, gastric emptying and glucose-dependent insulin release.
Tirzepatide, from Eli Lilly, is a dual agonist: it acts at both the GIP and the GLP-1 receptor. GIP is the other major incretin hormone, and that second target is why tirzepatide is a different class of molecule rather than a stronger version of the same one.
Advocates of reduced-dose tirzepatide point to that second receptor, reasoning that two pathways engaged lightly may behave differently from one. That is pharmacological reasoning, not trial evidence. The full-dose molecular comparison is in tirzepatide vs semaglutide compared.
Two Approved Ladders That Start in Different Places
The labels do not climb the same staircase, and this changes the microdosing conversation more than anything else.
Per the Wegovy prescribing information, semaglutide injection starts at 0.25 mg weekly for four weeks and escalates every four weeks toward a usual maintenance dosage of 2.4 mg weekly. Per the Zepbound prescribing information, tirzepatide starts at 2.5 mg weekly for four weeks and rises in 2.5 mg increments no sooner than every four weeks, to a maximum of 15 mg weekly.
Those figures describe the approved brand labels. They are not dosing guidance, they are not microdoses, and milligrams do not translate between the molecules. Titration mechanics sit in the semaglutide dosage chart and the tirzepatide dosage guide.
Microdosing Tirzepatide vs Semaglutide: Head-to-Head
| Tirzepatide | Semaglutide | |
|---|---|---|
| Drug class | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| FDA-approved brands | Mounjaro (type 2 diabetes); Zepbound (chronic weight management, plus obstructive sleep apnea in adults with obesity) | Ozempic (type 2 diabetes); Wegovy (weight reduction, cardiovascular risk reduction, noncirrhotic MASH) |
| Label starting rung (brand, not guidance) | 2.5 mg weekly for four weeks | 0.25 mg weekly for four weeks (injection) |
| Label escalation | 2.5 mg steps, no sooner than every four weeks, maximum 15 mg weekly | Every four weeks toward maintenance of 2.4 mg weekly |
| Approved oral form | None | Yes, an approved daily tablet exists |
| Brand presentations | Pens and vials, all filled to the label's fixed increments | Pens, syringes and tablets, all in the label's fixed strengths |
| Where reduced dosing happens | Compounded vials from licensed US compounding pharmacies | Compounded vials from licensed US compounding pharmacies |
| Is microdosing FDA-approved | No, and compounded tirzepatide is not FDA-approved either | No, and compounded semaglutide is not FDA-approved either |
| Boxed warning | Thyroid C-cell tumours in rodents; contraindicated with personal or family history of MTC or MEN 2 | Thyroid C-cell tumours in rodents; contraindicated with personal or family history of MTC or MEN 2 |
| Phase 3 microdose evidence | None | None |
The bottom two rows matter most. On the questions people actually ask about microdosing, the molecules sit in the same position: outside the approved framework, and without phase 3 data.
If a reduced-dose approach sounds closer to what you want than climbing a standard ladder, the next step is a written intake a licensed provider reviews. Pricing is as low as $116 per month, down from $279, as of publication.
See microdosed tirzepatideFormat Is the Practical Constraint
Both brands are supplied only in the strengths their labels specify, whether the presentation is a pen, a prefilled syringe or a vial. No brand presentation is designed to deliver an amount between the labelled rungs.
That is the structural reason reduced-dose prescribing happens with compounded medication in a vial, where a provider can specify an amount outside the fixed brand increments. Compounded tirzepatide and compounded semaglutide are prepared by licensed US compounding pharmacies and are not FDA-approved. The device question is unpacked in pens vs compounded vials and why microdosing requires compounding.
Semaglutide does have one format tirzepatide has no approved equivalent for: an oral tablet. For someone who will not inject, that is a real difference, though the tablet is a labelled product with its own escalation schedule, not a microdose. More in what is semaglutide.
What the Evidence Covers, and What It Does Not
A direct head-to-head trial exists. SURMOUNT-5 randomly assigned 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of tirzepatide or of semaglutide, weekly for 72 weeks. Least-squares mean weight change at week 72 was reported as -20.2 percent with tirzepatide and -13.7 percent with semaglutide.
That trial studied maximum tolerated labelled doses, and tells you nothing about either molecule at a reduced dose. Findings in a trial population are not a forecast for any individual, and a full-dose result cannot be read across to microdosing.
No large randomised trial has established microdose efficacy for either molecule. The rationale is pharmacological reasoning plus clinical experience, and anyone claiming more is describing evidence that does not exist. See what the microdosing research shows.
How the Reduced-Dose Experience Differs
In that trial, the most common adverse events in both groups were gastrointestinal, mostly mild to moderate, occurring primarily during dose escalation. That escalation pattern is what reduced-dose prescribing is built on, but a lower amount is no guarantee of fewer symptoms, and tolerance varies unpredictably between molecules.
Both molecules carry a boxed warning for thyroid C-cell tumours seen in rodents, and both are contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Reducing an amount does not change a contraindication. Symptom patterns are covered in microdosing GLP-1 side effects and, for the other molecule, microdosing semaglutide.
What a Provider Weighs
Neither molecule is a default, and neither reduced-dose approach is proven safer or more effective than standard dosing. A provider is reading a specific person, not picking a winner.
The inputs are health history and current medications, contraindications including the thyroid history above, previous GLP-1 experience and tolerability, which approved indications are relevant, and whether injection is acceptable. Telos Rx is online-first and asynchronous: you complete a written intake, a licensed provider reviews it without a scheduled appointment, and everything is subject to medical approval by a licensed provider. Approval is not guaranteed.
Reduced versus standard dosing is compared in microdose vs standard tirzepatide, scheduling in microdosing tirzepatide schedule, and programs in Telos Rx vs Noom microdose.
Keep Reading
- What Counts as a Microdose of Tirzepatide?
- Microdosing GLP-1 Side Effects: What Changes
- Tirzepatide Dosing in mL: Why There Is No Calculator
Frequently Asked Questions
Can you microdose semaglutide?
A provider can prescribe semaglutide below the labelled titration ladder if they judge it appropriate for an individual, but there is no approved microdose product and no official definition of the amount. Brand pens and syringes are filled to the label's fixed strengths, so reduced-dose prescribing in practice uses compounded medication in a vial, which is not FDA-approved.
Is microdosing tirzepatide better than microdosing semaglutide?
Nobody can answer that from evidence, because neither molecule has phase 3 microdose data. The head-to-head trial that favoured tirzepatide compared maximum tolerated labelled doses, not reduced ones, so it does not transfer. They are different tools with different receptor targets, and the choice belongs to a licensed provider assessing an individual.
Is a microdose of semaglutide the same amount as a microdose of tirzepatide?
No, and comparing the milligram numbers is misleading. The two labels start in different places and escalate in different increments, so a figure that looks small on one label is not equivalent to the same figure on the other. Any amount used outside the label is determined by a provider for a specific person, never chosen from an article.
Is microdosing FDA-approved?
No. Microdosing is not an FDA-approved use of either molecule, there is no approved microdose label, and compounded tirzepatide and compounded semaglutide are not FDA-approved products. They are prepared by licensed US compounding pharmacies under federal compounding regulations against a prescription written for an individual patient.
Can you microdose using a Zepbound or Wegovy pen?
Brand presentations are supplied in the strengths their labels specify, so there is no brand device built to deliver an amount between the labelled rungs. That structural limit is the reason reduced-dose prescribing happens with compounded medication supplied in a vial, where a provider can specify an amount outside the fixed brand increments.
Which molecule is easier to tolerate at a reduced dose?
There is no trial that answers this. In the full-dose head-to-head trial, gastrointestinal effects were the most common adverse events in both groups and occurred primarily during escalation. Individual tolerance varies, both molecules carry the same boxed warning and contraindications, and a provider weighs your history rather than a general ranking.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Ready to find out whether a reduced-dose approach fits you? Start with the microdosed tirzepatide page, where pricing is as low as $116 per month against $279 as of publication, with free 48-hour shipping if approved, FSA and HSA accepted and cancellation at any time. Then complete the written intake: start an online visit. A licensed provider reviews every request, and approval is not guaranteed.